Close Menu

More articles about Disease Areas

The firm's head of strategy said now that it is a public company and paying down debt, Ortho can consider acquisitions that had been out of its reach.

Laboratory staffing and supply shortages limited patient access to cancer screening tests, and the pandemic decreased the development and validation of new tests.

In a recent commentary, the officials recounted the various factors that led to a troubled rollout of SARS-CoV-2 serology testing this spring.

A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.

The fecal calprotectin test, which runs on the company's ProciseDx immunoassay system, is designed to help in the diagnosis of Crohn's disease and ulcerative colitis.

Under the Ge-Med project, University Hospital Tübingen will offer diagnostic whole-genome sequencing for all genetic indications and will include PRS in its reporting.

The expanded partnership includes a commercial agreement for the ClonoSeq and ImmunoSeq assays, as well as a lab service agreement for the T-Detect COVID test.

The lab will use its phlebotomy network to help Grail with specimen collection for its Galleri multi-cancer early detection blood test, slated to launch this year.

Cue said that US-based K-12 schools, essential businesses, nursing homes, hospitals, and physicians' offices are already using its COVID-19 test. 

The kit helps in the qualitative and semi-quantitative determination of anti-double stranded DNA IgG antibodies with the use of fluorescence microscopy.

The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.

The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.

The test qualitatively detects SARS-CoV-2 nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens and provides results in as little as 15 minutes.

The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.

PreludeDx's DCISionRT test is for women diagnosed with ductal carcinoma in situ or stage 0 breast cancer who are treated with breast-conserving surgery.

The company said that it has submitted the high-throughput antigen test to the US Food and Drug Administration for Emergency Use Authorization.

The company has performed 100,000 rapid tests for SARS-CoV-2 to date for a variety of organizations, including sports leagues and public schools.

Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.

The agency cautioned test companies that the presence of mutations in the virus could lead to false negative results.

LightDeck said it is developing a six-minute test to offer better performance than current lateral flow tests that need 15 minutes or more to return a result.

Pages